Cargando…
Acid ceramidase is upregulated in AML and represents a novel therapeutic target
There is an urgent unmet need for new therapeutics in acute myeloid leukemia (AML) as standard therapy has not changed in the past three decades and outcome remains poor for most patients. Sphingolipid dysregulation through decreased ceramide levels and elevated sphingosine 1-phosphate (S1P) promote...
Autores principales: | Tan, Su-Fern, Liu, Xin, Fox, Todd E., Barth, Brian M., Sharma, Arati, Turner, Stephen D., Awwad, Andy, Dewey, Alden, Doi, Kenichiro, Spitzer, Barbara, Shah, Mithun Vinod, Morad, Samy A.F., Desai, Dhimant, Amin, Shantu, Zhu, Junjia, Liao, Jason, Yun, Jong, Kester, Mark, Claxton, David F., Wang, Hong-Gang, Cabot, Myles C., Schuchman, Edward H., Levine, Ross L., Feith, David J., Loughran, Thomas P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347763/ https://www.ncbi.nlm.nih.gov/pubmed/27825124 http://dx.doi.org/10.18632/oncotarget.13079 |
Ejemplares similares
-
The novel Isatin analog KS99 targets stemness markers in acute myeloid leukemia
por: Annageldiyev, Charyguly, et al.
Publicado: (2020) -
Ceramide nanoliposomes augment the efficacy of venetoclax and cytarabine in models of acute myeloid leukemia
por: Khokhlatchev, Andrei V., et al.
Publicado: (2022) -
The PI3K/AKT Pathway Inhibitor ISC-4 Induces Apoptosis and Inhibits Growth of Leukemia in Preclinical Models of Acute Myeloid Leukemia
por: Annageldiyev, Charyguly, et al.
Publicado: (2020) -
DJ4 Targets the Rho-Associated Protein Kinase Pathway and Attenuates Disease Progression in Preclinical Murine Models of Acute Myeloid Leukemia
por: Golla, Upendarrao, et al.
Publicado: (2021) -
Acute myeloid leukemia stratifies as two clinically relevant sphingolipidomic subtypes
por: Paudel, B. Bishal, et al.
Publicado: (2023)